



The

IMPROVE-CKD

AKTN 10.01

Results

trial

What we learned

The trial looked at whether lowering a mineral in the body called phosphate with a medication called lanthanum carbonate could reduce the risk of heart and blood vessel disease in people with chronic kidney disease.



278 adults with chronic kidney disease



18 hospitals: Australia, New Zealand & Malaysia



Participants received lanthanum carbonate or placebo



2 Years

The results of this trial tell us that lanthanum carbonate did not reduce the risk of heart and blood vessel disease.

We now know that prescribing this medication to lower phosphate levels won't necessarily reduce the chance of people with chronic kidney disease having problems with heart and blood vessel disease.



Australasian Kidney Trials Network
www.aktn.org.au

Registration: ANZCTRN12610000650099.
Protocol: 10.01

